LONDON (Reuters) - AstraZeneca Chief Executive David Brennan is to step down on June 1 in an abrupt exit after six years in the top job, following rising investor discontent at the company's performance. Britain's second-biggest drugmaker has suffered repeated drug development setbacks, stoking fears about its long-term prospects given a complete reliance on prescription medicines at a time when rivals have diversified. ...
Original Source
No comments:
Post a Comment